How to Stop Stomach Bleeding From Aspirin

Stomach bleeding caused by aspirin is a medical emergency that you cannot safely manage on your own at home. If you notice black, tarry stools, vomit that looks like coffee grounds, or feel lightheaded and unusually fatigued, you need to get to an emergency department. Once there, the standard approach combines intravenous fluids and blood products as needed, powerful acid-suppressing medication, and often an endoscopic procedure to locate and seal the bleeding site. The trickier question, and one that affects long-term outcomes just as much, is what happens after the acute bleed is controlled.

How to Tell Your Stomach Is Bleeding

Aspirin can cause bleeding anywhere along the upper digestive tract, from the stomach lining to the first part of the small intestine. The signs depend on how fast the blood is flowing. A slow, chronic bleed often shows up as iron-deficiency anemia: you feel worn out, short of breath with minor effort, and pale. Your stools may appear darker than usual without being obviously bloody. A faster bleed is harder to miss. Stools become black and sticky (sometimes described as tar-like), or you may vomit material that resembles dark coffee grounds. Bright red blood in vomit signals brisk, active bleeding and is the most urgent scenario.

Many people on daily low-dose aspirin lose small amounts of blood through the gut without ever knowing it. This “occult” bleeding only turns up on lab tests, but over months it can quietly drain your iron stores and leave you anemic. If you take aspirin regularly and your doctor finds unexplained anemia, aspirin-related mucosal damage is high on the list of suspects.

Why Aspirin Damages the Stomach Lining

Aspirin works by shutting down an enzyme called cyclooxygenase, or COX. That is how it prevents blood clots, but COX also produces substances called prostaglandins that keep your stomach’s protective mucus layer thick and well-supplied with blood. When aspirin suppresses COX activity in the stomach lining, prostaglandin levels drop, the mucus barrier thins, and acid can eat into exposed tissue, forming ulcers that bleed.¹ This is not a local irritation effect from the pill sitting in your stomach. It is a systemic, whole-body suppression of the protective chemistry, which is why changing the pill’s coating does not solve the problem.

What Happens When You Arrive at the Hospital

The first priority is stabilizing you. That means intravenous fluids to restore circulating volume and, if your blood count has dropped enough, blood transfusions. In patients with heart disease, doctors tend to transfuse earlier rather than later because a low red blood cell count starves the heart muscle of oxygen.²

While resuscitation is underway, doctors score the severity of the bleed using tools like the Glasgow-Blatchford Score. A score of zero or one reliably identifies people who do not need an urgent endoscopy and can safely be managed as outpatients.³ Among the available scoring systems, the Glasgow-Blatchford Score consistently shows the best ability to predict who actually needs an intervention or is at risk of dying in the hospital.⁴ For everyone else, endoscopy typically follows within 24 hours.

Endoscopy and Stopping the Bleed

During an upper endoscopy, a gastroenterologist threads a thin, flexible scope down the throat to find the bleeding source. Once the ulcer or erosion is located, several techniques can seal it. Clips can be placed directly over the bleeding vessel, functioning like tiny staples. Heat (thermocoagulation) can be applied to cauterize the site. Epinephrine can be injected into the surrounding tissue to constrict blood vessels and slow the flow temporarily. Research shows that clipping on its own reduces both the rate of rebleeding and the need for surgery when compared to epinephrine injection alone, and it matches thermocoagulation in effectiveness.⁵ In practice, doctors often combine techniques, such as injecting epinephrine first and then placing a clip or applying heat.

Acid Suppression Is the Cornerstone

Controlling stomach acid after a bleed is just as important as the endoscopy itself. Proton pump inhibitors, commonly known as PPIs (drugs like omeprazole, esomeprazole, lansoprazole, and pantoprazole), are the standard treatment. A large meta-analysis found that PPIs cut the risk of aspirin-related upper GI ulcers by about 84% and reduced bleeding events by roughly 73% compared to placebo or no treatment.⁶ Those are striking numbers, and they explain why virtually every guideline recommends a PPI for anyone on aspirin who has had a GI bleed.

PPIs also outperform the older class of acid suppressors, H2-receptor antagonists (drugs like ranitidine and famotidine). The same meta-analysis found PPIs were superior to H2-receptor antagonists for both preventing ulcers and preventing bleeding in aspirin users.⁶ H2 blockers are still better than nothing, but if you have a history of aspirin-related bleeding, a PPI is the stronger shield.

The Aspirin Dilemma After a Bleed

Here is where things get genuinely difficult. If aspirin caused the bleed, the obvious instinct is to stop taking it. But most people on daily aspirin are on it for a reason: a prior heart attack, a stent, established cardiovascular disease. Stopping aspirin abruptly carries real danger. A large population-based study found that people who discontinued low-dose aspirin had a 37% higher rate of cardiovascular events compared to those who continued, amounting to roughly one additional cardiovascular event per year for every 74 people who stop.⁷ The risk rose quickly after discontinuation and did not fade over time.

So the decision is rarely “stop aspirin forever.” Instead, it is usually “hold aspirin briefly while the acute bleed is managed, then restart it alongside a PPI as soon as it is safe.” The exact timing depends on how severe the bleed was, whether the ulcer is healing, and how high your cardiovascular risk is. Your cardiologist and gastroenterologist typically coordinate that call together.

Aspirin Plus a PPI Beats Switching to Clopidogrel

A common misconception is that if aspirin caused a stomach bleed, you should simply switch to clopidogrel (Plavix) as a “gentler” alternative. A landmark trial tested this head-to-head: patients with a history of aspirin-induced ulcer bleeding were randomly assigned to receive either clopidogrel alone or aspirin plus the PPI esomeprazole. Over 12 months, rebleeding occurred in about 8.6% of the clopidogrel group but only 0.7% of the aspirin-plus-PPI group.⁸ In other words, keeping aspirin and adding a PPI was far safer for the gut than abandoning aspirin for clopidogrel. A separate systematic review confirmed the same pattern, finding that aspirin plus a PPI dramatically reduced recurrent upper GI bleeding events compared to clopidogrel alone.⁹

For people on dual antiplatelet therapy (aspirin plus clopidogrel, often after a stent), the same meta-analysis found that adding a PPI prevented GI bleeding without increasing the risk of major cardiovascular events.⁶ That finding matters because there was a period when doctors worried that PPIs might blunt clopidogrel’s effectiveness. The evidence now indicates the cardiovascular risk is not increased.

Enteric Coating Does Not Protect You

Many people believe that enteric-coated or buffered aspirin is easier on the stomach. The evidence says otherwise. A study comparing plain, enteric-coated, and buffered aspirin at low doses (325 mg or less per day) found the risk of major upper GI bleeding was essentially the same across all three formulations, with relative risks of 2.6, 2.7, and 3.1 respectively.¹⁰ There was no difference by bleeding site either, whether the bleed came from the stomach or the duodenum. The researchers concluded bluntly that the assumption these coatings are less harmful “may be mistaken.” This makes biological sense: aspirin’s gut damage is primarily systemic, driven by the suppression of protective prostaglandins throughout the body, not by the pill dissolving in the stomach.

Risk Factors That Amplify the Danger

Not everyone on aspirin faces the same bleeding risk. Certain factors stack on top of aspirin’s baseline effect and make bleeds substantially more likely.

Helicobacter Pylori Infection

This common stomach bacterium is an independent risk factor for upper GI bleeding in aspirin users. One study found that H. pylori infection roughly quadrupled the odds of bleeding in patients taking low-dose aspirin.¹¹ H. pylori damages the stomach lining through its own mechanisms, and when you add aspirin’s prostaglandin-stripping effect on top, the result is a much more vulnerable mucosal barrier. Testing for and eradicating H. pylori before starting long-term aspirin therapy is now a standard recommendation for anyone at higher bleeding risk.

SSRI Antidepressants

Selective serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, also impair platelet function by depleting serotonin stores in platelets. Combining an SSRI with aspirin raised the risk of GI bleeding by about 27% in one study.¹² A separate study after heart attacks found a similar pattern, with the combination of aspirin and an SSRI carrying roughly 42% higher bleeding risk than aspirin alone.¹³ When all three were combined (aspirin, clopidogrel, and an SSRI), the bleeding risk was more than double that of aspirin alone. If you take both aspirin and an SSRI, this is worth discussing with your doctor, especially if you have other risk factors like older age or a history of ulcers.

Other Common Risk Multipliers

Advanced age, a history of prior ulcers or GI bleeding, concurrent use of corticosteroids, and use of other anti-inflammatory drugs alongside aspirin all increase the odds of a bleed. Alcohol use compounds the problem further. The more of these factors you carry, the stronger the case for prophylactic acid suppression with a PPI.

When Endoscopy Cannot Stop the Bleeding

In a small percentage of cases, endoscopic treatment fails. The ulcer keeps bleeding despite clips, cautery, and injection. Historically, the next step was emergency surgery, which carries significant risks in patients who are already unstable and often elderly. Over the past two decades, transcatheter arterial embolization has emerged as the preferred alternative. In this procedure, an interventional radiologist threads a catheter through the arterial system to the vessel feeding the ulcer and blocks it with tiny particles, coils, or glue. One series reported a technical success rate of 100% (the vessel was reached and blocked every time) and a clinical success rate of about 78%.¹⁴

A population-based comparison found that embolization compared favorably with surgery in terms of overall prognosis after refractory peptic ulcer bleeding. Patients who underwent embolization had shorter hospital stays and fewer complications, though they did face a somewhat higher risk of rebleeding afterward.¹⁵ For high-risk patients who might not survive emergency abdominal surgery, embolization is now often recommended as the first-line salvage treatment.¹⁶

Mucosal Protectants Beyond PPIs

PPIs work by suppressing acid production, but they are not the only protective option. Mucosal protectants take a different approach: rather than reducing the acid, they strengthen the stomach’s defenses against it. Rebamipide, widely used in parts of Asia, boosts prostaglandin synthesis, scavenges damaging free radicals, and enhances mucin production, effectively doing some of the work that aspirin undoes.¹⁷ A large observational study found that rebamipide reduced the risk of occult GI bleeding in anti-inflammatory drug users by roughly 57%, and misoprostol (a prostaglandin analog) reduced it by about 53%.¹⁸ PPIs still offered the strongest protection in that study, but the mucosal agents provided a meaningful benefit, and they work through a complementary mechanism. Some gastroenterologists prescribe rebamipide alongside a PPI for patients at especially high risk.

Rebamipide is not widely available in every country (it is not approved by the FDA in the United States, for instance), which limits its practical use for many readers. Misoprostol is more broadly available but causes dose-dependent diarrhea and cramping, which limits how well patients tolerate it.

Vonoprazan and the Future of Acid Suppression

PPIs are excellent drugs, but they have quirks. They take days to reach full acid-suppressing effect, they need to be taken on an empty stomach before meals, and their potency varies considerably from person to person depending on genetics. A newer class of acid blocker, called potassium-competitive acid blockers, addresses several of these limitations. Vonoprazan, the first widely available drug in this class, was approved in the United States in 2024 for related conditions and is being studied for ulcer bleeding prevention.

In head-to-head crossover studies, vonoprazan maintained stomach pH above 4 for about 62% of the first day, compared to roughly 23% for the PPI lansoprazole. By one week, vonoprazan achieved a mean gastric pH of 5.9, and its half-life was more than five times longer than lansoprazole’s.¹⁹ Faster onset matters because in the first hours after an endoscopic procedure on a bleeding ulcer, strong acid suppression reduces the chance the clot will dissolve and the bleed will restart. Vonoprazan’s speed and potency make it a promising candidate for replacing or supplementing intravenous PPIs in that critical window, though more trial data is still needed.

Why the Same PPI Dose Does Not Work for Everyone

If you have taken a PPI and still developed aspirin-related stomach problems, your genes may be partly to blame. PPIs are broken down in the liver primarily by an enzyme whose activity varies substantially across the population depending on your genetic makeup. People who metabolize PPIs very quickly (“rapid metabolizers”) clear the drug from their system faster, meaning they get weaker and shorter-lasting acid suppression from the same dose. Separate genetic variations in the stomach’s own acid-producing pump also affect how responsive your acid secretion is to suppression.²⁰ In practice, this means some people need a higher PPI dose, or twice-daily dosing, or a switch to a different PPI to get adequate protection. Vonoprazan’s metabolism is less dependent on these genetic pathways, which is another reason the newer drug is generating interest.

If you have been on a standard PPI dose and still developed an ulcer or bleed while taking aspirin, it is worth asking your doctor whether a dose adjustment, a medication switch, or in some health systems, pharmacogenomic testing might help. The answer is not always “PPIs failed,” it may be “that particular PPI at that particular dose was not enough for your biology.”